Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271167 · ClinicalTrials.gov registry record · Phase 2
A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass
A Phase 2 study, sponsored by Inotek Pharmaceuticals Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00271167 is a Phase 2 study that was terminated before completion, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 162 participants.
The verdict
NCT00271167, a Phase 2 study, was terminated before completion, sponsored by Inotek Pharmaceuticals Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.
Interventions
- DRUG INO-1001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00271167
The ClinicalTrials.gov registry entry for NCT00271167 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inotek Pharmaceuticals Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INO-1001 is the first listed.
NCT00271167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00271167 about?
NCT00271167 is a clinical study titled "A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass". The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.
What is the current status of trial NCT00271167?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00271167?
The interventions under investigation include: INO-1001 (DRUG).
Who is sponsoring clinical trial NCT00271167?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.